Finanzen von Mustang Bio Inc (MBIO)MBIOMustang Bio Inc

Evaluating the bottom line, Mustang Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.12%, provide a clear picture of how effectively MBIO converts its operational activities into shareholder value.

In the context of the broader market, MBIO competes directly with industry leaders such as KALA and ERNA. With a market capitalization of $2.99M, it holds a significant position in the sector. When comparing efficiency, MBIO's gross margin of N/A stands against KALA's N/A and ERNA's N/A. Such benchmarking helps identify whether Mustang Bio Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with a net income loss of $1,072,000 in Q2 2026 and a gross profit of $0 for multiple quarters. The forward P/E ratio is 0, indicating no expected earnings, and the current ratio is 1.97, suggesting some liquidity but not enough to offset the ongoing losses.